Post-Trasplant Lymphoproliferative Disorders (PTLD) in Adult Kidney Trasplantated Patients by Aversa, Savina et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
5 
Post-Trasplant Lymphoproliferative Disorders 
(PTLD) in Adult Kidney Trasplantated Patients 
Savina Aversa, Silvia Stragliotto, Fabio Canova,  
Boso Caterina and Marino Dario 
Istituto Oncologico Veneto, IRCC, Padova,  
Italy 
1. Introduction 
Post-transplant lymphoproliferative disorder is a clearly recognized and potentially life 
threatening complication after solid organ or bone marrow transplantation. It comprises a 
spectrum of diseases ranging from infectious mononucleosis and lymphoid hyperplasia to 
highly aggressive lymphoma.  
PTLD is a relatively common malignancy after transplantation with a reported incidence 
ranging from 2% to 10%. It’s the most common form of post-transplant malignancy after 
skin cancer with an overall mortality often exceeding 50% (Purtilo et al., 1980; Leblond et al., 
1995). Most cases of PTLD are associated with Epstein Barr virus (EBV) that leads to 
uncontrolled B cell proliferation in patients with a decreased function of EBV specific T cell 
because of immunosuppressive drugs. PTLD is not exclusively associated with EBV 
infection as EBV-negative PTLD, often developing late after transplantation. 
Post transplant lymphomas differ from lymphomas in general population in 
histopathological findings, increased extranodal involvement, a more aggressive clinical 
course and poorer response to conventional treatment.  
Registry-based reports however usually do not provide details of treatment and outcome: 
the existing single institution studies are largely reports and only a few studies include a 
significant number of patients with PTLD. Treatment of PTLD consists always in reduction 
of immunosuppression as first step. The role of chemotherapy remains unclear. In the past it 
was reserved for patients in whom other treatment options have failed even if the increased 
toxicities from cytotoxic agent, the high susceptibility to life-threatening infections. Actually 
most authors consider new anti CD20 mAB essential for treatment or as single agent or in 
association with CT but there is not a definitive agreement about schedules, duration of 
treatment and setting of patients. 
2. Epidemiology 
The incidence of PTLD varies according to organ transplanted, the nature of the 
immunosuppressive regimen and the presence or absence of EBV infection before 
transplantation and the age of patients. In adults PTLD has been reported to occur in 1-2,3% of 
kidney transplants, 1-2,8% of liver transplants, 1-6,3% of heart transplants, 2,4-5,8% of hearth-
lung transplants, 4,2-10 of lung transplants and up to 10% of small bowel transplants (Table 1).  
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Transplanted Organ Incidence of PTLD 
Kidney 1-2,3 % 
Liver 1-2,8 % 
Heart 1-6,3 % 
Lung 4,2-10 % 
Heart/Lung 2,4-5,8 % 
Bowel 10 % 
Table 1. Incidence of PTLD according to transplanted organ 
The incidence is significantly higher in paediatric recipients and has been reported in 1, 2-
10% of kidney transplants, 4-15% of liver transplants and 6, 4-19,5 of hearth, lung and hearth 
and lung transplants. The higher incidence of PTLD in paediatric transplant recipient is 
attributable in large part to the development of primary EBV infection after transplantation. 
However the true incidence of PTLD in adult and paediatric recipients is difficult to 
determine with accuracy (Dror et a., 1999; Libertiny et al., 2001; Opelz et al., 1993) PTLD is 
surprisingly uncommon (<1 %) in the setting of allogenic bone marrow transplantation in 
the absence of specific T-cell manipulation such as use of a monoclonal anti CD3 antibody or 
T cell depletion of donor marrow. Although PTLD may occur at any time after 
transplantation, the risk of developing PTLD is greatest within the first year and declines 
over time thereafter. A report by the Transplant Collaborative Study showed the incidence 
of PTLD to be 224/100000 in the first year, 54/100000 in the second year and 31/100000 in 
the sixth year following transplantation (Bastard et al., 1994; Lo Coco et al., 1994; Cesarman 
et al., 1998; Opelz et al., 2003) 
3. Pathogenesis 
PTLD is often associated with clinical or serological reactivation of Epstein Barr virus 
infection. Tumour tissues often contain EBV-DNA sequences and express viral protein 
(Purtilo et al., 1980; Young et al., 1989; Hanto et al., 1981). In normal individuals, host 
defence mechanism make EBV infection a self limited disease and B cell proliferation is 
controlled by specific T cell lymphocytes. The infection is however not eradicated but 
persists in clinical latent form. In transplanted patients, partial suppression of T lymphocyte 
to prevent graft rejection, makes EBV-driven B cell proliferation uncontrolled and 
predispose to development of PTLD. EBV seronegative patients had a 10-76 times greater 
incidence of PTLD than EBV seropositive recipients (Walker et al., 1995). Active viral 
replication in immunosuppressed patients results in the expression of EBV encoded genes 
including oncogenes as LMP1, a gene that  inhibits apoptosis by up regulating the anti-
apoptotic gene BCL-2 (Kulwichit et al., 1998). Others alterations are involved in some PTLD, 
including the accumulation of cellular genetic alteration of p53, N-ras and c-myc 
rearrangements. BCL-6, that encodes a transcriptional repressor gene rearranged in 35-40% 
of diffuse large B cell lymphoma in immunocompetent patients (Bastard et al., 1994; Lo Coco 
et al., 1994) presents frequent somatic mutations in PTLD representing probably a consistent 
step in the progression from a PTLD that can be controlled by a reconstituted immune 
system to one that will require more aggressive therapeutic intervention (Ceserman et al., 
1998). Additional stimuli are required to promote the development of PTLD and, although 
these are not clearly defined, the local cytokine environment and chronic stimulation of B 
cell by alloantigen are thought to be important. 
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4. Risk factors 
The most important risk factor for PTLD development is the intensity of immunosuppression. 
Induction and rejection treatment with anti-T cell antibodies, especially OKT3 and ATG may 
lead to an increased risk of PTLD, as demonstrated by the higher incidence of early PTLD in 
hearth and hearth/lung recipient. With longer follow-up, is now evident that antibody 
prophylaxis increased the risk of lymphoma primarily during the first post-transplant year, 
whereas in subsequent years the risk is similar to that in non antibody-treated patients. 
Whether IL-2 receptor blocking monoclonal antibody, which was introduced in the late 1990s, 
also increases the risk of lymphoma is of great interest. Analysis of the critical 12-months data 
showed that use of anti IL-2 receptor antibodies was not associated with an increased risk of 
lymphoma (Gao et al., 2004) (Figure 1). There is no conclusive evidence that development of 
PTLD is associated with a single immunosuppressive agent (Gao et al., 2003; Pirsch et al., 1997; 
Weisner et al., 1998; Younes et al., 2000). Also the effect of everolimus and sirolimus on PTLD 
development is not clear. These drugs may theoretically be associated with a lower risk as 
demonstrated in animal model but the lack of prospective randomized trial assessing these 
differences restrains any firm conclusion (Yakupoglu et al., 2006; Majewski et al., 2003; Kusuki 
et al., 2009). A special category of patient at risk (10 to 50 fold increased risk) are EBV 
seronegative patients receiving allograft from EBV seropositive donors, leading to primary 
EBV infection (Walker et al., 1995). This is also the reason for the higher incidence of early 
PTLD observed in paediatric transplant recipients who often are still EBV seronegative at the 
time of transplantation.  
A high incidence of EBV related lymphoproliferative disorders has been reported in a 
number of congenital immunodeficiency syndromes including severe combined 
immunodeficiency (SCID), ataxia teleangiectasia and Wischott Aldrich syndrome 
(Waldmann et al., 1983). Acquired immunodeficiency due to HIV disease has become a 
major clinical problem in many parts of the world. An increased incidence of aggressive non 
Hodgkin lymphoma which shares many of the unusual characteristics of PTLD is a 
manifestation of AIDS. The introduction of HAART has dramatically reduced the incidence 
of this life threatening manifestation of HIV. 
Finally, the underlying indication for transplantation may also influence the risk for PTLD. 
For example hepatitis C infection  (Burra et al., 2006)  is associated with a particularly high 
risk of PTLD. 
5. Pathologic features 
A standardized approach to the classification of PTLD is important to allow consistency of 
reporting and to enable comparison of different treatments. Histology is essential also in 
differentiation between rejection and PTLD involvement of the graft. The classification of 
PTLD currently used is based on the histopathological appearance of the tumour. PTLD can 
be divided into three distinct morphological groups, as reported by the World Health 
Organization classification of neoplastic disease of the haematopoietic and lymphoid tissues 
(Table 2).  
The first group comprises diffuse B cell hyperplasia, characterized by differentiated plasma 
cell and preservation of the normal lymphoid architecture. This type of PTLD is most often 
seen in children and young adults, usually occurs within the first year following 
transplantation and responds well to reduction in immunosuppression (Kahan et al., 2000). 
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The second group comprises polymorphic PTLD characterised by nuclear atypia, tumour 
necrosis and destruction of underlying lymphoid architecture. Lesions in this group are 
highly polymorphic, usually monoclonal and include plasmacytes and blast form. 
Polymorphic PTLD is the most common type of PTLD in both children and adults and may 
occur at any time after transplantation. 
The third group comprises monomorphic PTLD and includes high grade invasive 
lymphoma of B or T lymphocytes. This type of PTLD is often seen several years after 
transplantation and resembles non Hodgkin lymphoma. Monomorphic B cell PTLD can be 
further divided into diffuse large cell lymphoma and Burkitt or Burkitt like lymphoma. 
PTLD may also present with discordant lesions, in which different histological subtypes can 
be present in a single patient. 
Although the association between EBV and PTLD is well established, the presence of EBV in 
tumour cell is not required for the diagnosis. So, according to the international classification, 
any lymphoma arising in the post-transplant patient is considered to be a PTLD. 
 
Category Characteristics 
Early lesion 
 
 
 
 
 
 
 
Polymorphic 
 
 
 
Monomorphic 
 
 
 
 
 
 
Hodgkin lymphoma and Hodgkin 
lymphoma like PTLD 
Polyclonal 
Reactive plasmacytic hyperplasia and  
infectious mononucleosis like presentation 
Partial architectural preservation of the 
involved tissue 
Younger age 
Regress spontaneously or after reduction of 
immunosuppression 
B-cell maturation 
Monoclonal 
Variable response to immunosuppression 
withdrawal 
Monoclonal malignant B cell lymphoma 
Diffuse large B cell lymphoma 
Burkitt or Burkitt like lymphoma 
Plasma cell myeloma 
Plasmacytoma like lesion 
Rarely T cell neoplasma including 
peripheral T cell lymphoma 
Mostly seen in allogenic bone marrow 
transplant recipients 
Table 2. World Health Organization Classification of Post-transplantation 
Lymphoproliferative Disorder Pathology 
At least 90% of PTLD that occur in solid organ transplant patients arise from recipient cells 
(Weissmann e al., 1995) and the opposite apply in the case of bone marrow transplantation. 
Donor derived PTLD in organ transplant patient may have a predilection for the allograft 
(Strazzabosco et al., 1997). Some authors have suggested that they may have a worse and 
some a better prognosis than recipient organ PTLD even if further studies are needed in this 
area (Lones et al., 1997; Howard et al., 1992). 
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6. Clinical presentation  
The clinical presentation of PTLD is highly variable; this syndrome may occur in nodal or 
extranodal sites as  single or multiples masses.  
Most patients present with fever (seen in 50%), lymphadenopathy (seen in 30%) or non-
specific symptoms such as tonsillitis (particularly children) and weight loss. Around 15% of 
patients present as an emergency with intestinal perforation (Kahan et al., 2000) or with 
fulminant PTLD characterised by disseminated systemic disease that clinically resembles 
septic shock (Orjuela et al., 2003) 
Keeping in mind that PTLD often presents at extra nodal sites (Bakker et al., 2005) (figure 2), 
including the allograft and digestive tract, there may be early signs and symptoms that should 
at least include PTLD in the differential diagnosis. This is especially true for allograft 
involvement of PTLD. Kidney transplant recipients with allograft involvement of PTLD often 
presents with renal dysfunction, hydronephrosis because of ureteral obstruction and fever. 
Lung transplant recipients may present with organ dysfunction. Because the GI tract is also 
frequently involved, GI signs and symptoms such as diarrhoea and bleeding may also lead to 
a diagnosis of PTLD, headache or confusion in case of CNS involvement, nasal airway 
obstruction in case of sinonasal PTLD involvement, or subtle orbital symptoms in case of 
orbital PTLD. Skin involvement is observed in approximately 5-10% of all PTLD patients and 
must be differentiated by other cutaneous malignancy, given the fact that organ allograft 
recipients have an increased risk for the development of cutaneous malignancy such as 
squamous and basal cell carcinoma (Allen et al., 2001; Maecker et al., 2007; Beynet et al., 2004). 
Given this myriad of nonspecific clinical signs and symptoms, often masquerading PTLD as 
infection or adverse drug effects or reactions, or even absence of symptoms at all, methods for 
early detection of PTLD in transplant recipients would be extremely valuable.  
 
 
Fig. 2. Primary site of post-transplant lymphoproliferative disorder (PTLD) presentation and 
time after transplantation in kidney and lung transplant recipients. PTLD localized in the 
allograft occurred significantly earlier after transplantation when compared with PTLD 
localized outside the allograft (median: 4.5 months, range: 1–99 months vs. median: 
51 months, range: 2–172 months, P = 0.001) (adapted from ref. Bakker NA clinical transplant 
2005, printed with the permission of Blackwell Publishing). 
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7. Diagnosis of PTLD 
The diagnosis of PTLD should be based on histological examination of biopsy tissue. 
Excision biopsy is preferable because PTLD may contain large areas of necrosis although 
needle biopsy may be acceptable when obtaining larger samples is impractical. Cytological 
preparation are useful, particularly in the analysis of effusion (Lechapt et al., 2001) and can 
provide adequate diagnostic material particularly if ancillary studies such as phenotypic, 
clonal and viral analysis are also performed. Tissue should be subjected to standard 
histology, examined for the presence of EBV by immunostaining or in-situ hybridization, 
cellular infiltrates characterised by relevant phenotypic markers and clonality estimated. 
Although it would be ideal to sample each tumour in cases of multicenter PTLD, this is 
seldom possible. Each tumour may represent a separate clone and the histological grade 
may be underestimated in multicentric cases. The surgeon run also the risk, in this case, of 
sampling a reactive node that may contain evidence of EBV infection, while the primary 
lymphomatous PTLD lies elsewhere. It is also useful consider biopsy of any lesion that 
respond in an atypical fashion, particularly if regression is documented in other concurrent 
lesion. The presence of PTLD within the graft itself may sometimes be mistaken for acute 
rejection and if there is diagnostic doubt, in-situ hybridisation for EBV encoded RNA, and 
PCR for VDJ heavy-chain rearrangements to determine clonality may be helpful. Molecular 
analysis of oncogenes and tumour suppressor genes will undoubtedly play an increasingly 
important role in predicting behaviour even if, at present, these techniques are not widely 
available and few genes have been analyzed 
There is no separate staging system for PTLD and it is currently staged using the same 
system as NHL in the normal population. Staging of the disease should include CT of the 
abdomen and thorax and bone marrow aspiration. FDG-PET scanning is increasingly used 
as an important tool in the visualization of malignant lymphoma, especially for the 
detection of extranodal localization and post-treatment evaluation and has shown to be 
superior over conventional diagnostic techniques to differentiate between residual masses 
as a result of vital tumour or scar tissue. Bakker et al. 45 (Bakker et al., 2006) reported 12 
patients whit a highly avid FDG PTLD. Additional sites of extranodal localization of PTLD 
not visualized on CT scanning were found in 50% of all patients (figure 3).   
Additional investigations should be performed as indicated, e.g. CT or magnetic resonance 
scan of the cranium and spinal cord or further gastrointestinal imaging.  
8. EBV DNA load monitoring after transplantation 
Early detection of PTLD may allow for prompt therapy and potentially decreased mortality. 
In addition elevation of EBV-DNA load in blood is considered to reflect aberrant EBV 
induced B-cell proliferation. For this reasons much effort has been put in developing 
methods that might identify patients at risk for developing PTLD by measuring the amount 
of circulating EBV-DNA in the peripheral blood.  
Despite the consensus that PTLD patients have a significantly higher EBV-DNA load 
compared with healthy EBV-seropositive donors or non-PTLD transplant recipients, it is still  
unclear which threshold values are predictive for PTLD. Many different threshold values 
have been reported, all with different sensitivity (60–100%) and specificity (71–100%) (Lee et 
al., 2005; Rowe et al., 2001; Tsai et al., 2002). Another limitation of EBV-DNA load 
monitoring may be the observation that PTLD developing late after transplantation is not 
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Fig. 3. Example of discordant finding. CT abdomen (A) and FDG PET fused with the same 
CT scan (B). Arrow indicates the histologically confirmed focal lesion with high uptake of 
FDG, whereas the CT scan (A) does not show any abnormalities at the site of high FDG 
uptake. The high uptake in the allograft, including the kidney calices and pyelum, is 
physiological, as is the modest uptake in liver and spleen 
necessarily associated with EBV (negative staining for EBV in the tumour), and may 
therefore develop without a concomitant rise in EBV-DNA load. Indeed, there are studies 
showing EBV-negative PTLD developing late after transplantation without a rise in EBV-
DNA load. These observations suggest that, although increased EBV-DNA load is generally 
considered to represent an increase in circulating EBV-positive tumour cells, these high 
EBV-DNA loads in reality may represent a separate population of proliferating B-cells that 
may have nothing to do with development of PTLD. Instead, these proliferating B-cells may 
only reflect a general state of decreased T-cell surveillance in the transplant recipient 
In conclusion, because of the many variables that may influence the immune response of the 
individual transplant recipient, such as level of immunosuppression, time after 
transplantation, concomitant infections, type of organ transplanted, but also genetic factors, 
an exact cut-off value of EBV-DNA load critical for the development of PTLD in the 
individual patient cannot be defined. Therefore, rising EBV-DNA loads in the individual 
patient, instead of using a cut-off value, may be more appropriate to identify the individual 
patient at risk for the development of PTLD. 
It has been suggested that concomitant combined monitoring of EBV-DNA load and EBV-
specific cytotoxic T lymphocytes (CTL) responses (the absence of which may be used as a 
marker for possible overimmunosuppression) might better identify the individual patient at 
risk for PTLD development. The positive predictive value of high EBV-DNA loads as a 
predictor for PTLD development might be improved with this method. Smets et al. (Smets et 
al., 2002) showed that high EBV-DNA loads in patients who underwent primary EBV 
infection were indicative for PTLD development only if there was a low concomitant 
cellular immune response.  
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9. IL 10 monitoring 
Some reports have suggested that levels of IL-10 might be predictive for PTLD development 
(Muti et al., 2003). Although the exact relationship between IL-10 and the development of 
PTLD has not been fully elucidated yet, IL-10 can act as an autocrine growth factor for EBV-
transformed B-cells. Although this may lead to higher local levels of IL-10, it seems doubtful 
that this is also reflected by a higher total IL-10 load in the peripheral blood of the transplant 
recipient. Given the small number of studies so far and the lack of evidence regarding the 
exact relation between IL-10 and the development of PTLD, the relevance for identification 
of the patient at risk for PTLD development is not clear. 
10. Clinical management 
The treatment of PTLD poses a major therapeutic challenge and, although there is reasonable 
agreement about the overall principles of treatment no controlled studies have been 
undertaken and most of the recommendations result from small cohorts at single institutions.  
Even if no uniform approaches to the treatment have emerged, general principles are largely 
shared. 
 Treatment must be individualised according to clinical situation and the type of organ 
transplanted 
 Unlike non-Hodgkin lymphoma in immunocompetent patients, PTLD can be 
eradicated by surgical resection 
 Reduction of immunosuppression is considered the first line treatment 
 Antiviral agents have showed to induce regression of disease in some cases 
 Chemotherapy, traditionally considered a last resort treatment, is associated with high 
response rate and long    progression free survival 
 Rituximab has emerged as treatment of choice especially in early PTLD after failure in 
reduce/withdrawal immunosuppression 
 Radiotherapy may be appropriate for treatment of localized PTLD together with 
reduction in immunosuppression 
10.1 Reduction of immunosuppression 
Reduction of immunosuppression is the initial treatment in all patients with PTLD with the 
aim of increase antitumor activity. In EBV driven PTLD, this may partially restores CTL 
function resulting in an increase of EBV specific CTLs and elimination of virally infected 
lymphocytes, including those which constitute the tumour. The approach to reduce 
immunosuppressive drugs needs to be carefully individualised and will depend on the 
nature and extent of disease, the type of transplant recipient (life or no-life supporting graft) 
and the time from transplantation. 
Steroids also are an important component of most chemotherapy regimen for PTLD and 
lymphoma in general. 
A response to reduction in immunosuppression is usually seen within 2-4 weeks (Green et 
al., 1999). Reduction of immunosuppression leads to long term disease remission in 40-86% 
of paediatric patients and 25-63% of adults. 
Features that predict response include a short interval between transplantation and PTLD 
and wild type BCL-6 (Ceserman et al., 1998). If PTLD develops within one year of the 
transplant up to 80% will respond to reducing in immunosuppression with a mortality of 
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40%. In contrast, after one year the response rate falls to 10% with 80% of mortality  
(Armitiag et al., 1991). 
10.2 The role of Rituximab 
PTLD is usually of B cell origin and the use of mAB to deplete B cell is a logical approach for 
treatment. Rituximab, a monoclonal antibody directed against CD20 antigen expressed on 
mature and immature B cells, results in profound and long-lasting depletion of B cell (6-8 
months), together with hypogammaglobulinemia.  
Rituximab is widely used in the treatment of diffuse large B cell lymphoma in 
immunocompetent patients with an overall survival at two years of 70% compared with 
57% of patients treated with chemotherapy alone (Coiffer et al., 2002) rituximab has also 
recently been used in the treatment of patients with PTLD after solid organ transplantation 
as an adjunct to reduction of immunosuppression or chemotherapy.  
The majority of the case reports describe the use of rituximab, at standard dose of 
375 mg/mq once a week for four consecutive weeks, in the early onset PTLD, but it might 
be effective also for patients with late onset PTLD.  
The patients treated with rituximab benefit from the short duration of such therapy in terms 
of response rate and less toxic effect. However, because of the high relapse rate observed in 
several studies, the combination of rituximab with cytotoxic drugs is recommended to be 
evaluated. 
10.3 Antiviral agents 
Because most PTLDs arise as a consequence of EBV infection, prophylactic measures should 
include avoiding over-immunosuppression of the recipient such as the use of anti-
lymphocyte preparations, antiviral agents, EBV vaccination, in-vitro generated EBV specific 
CTL lines and avoiding, in EBV seronegative recipients, transplantation with an organ from 
an EBV positive donor.  
Regression has been described following high dose acyclovir (Hanto et al., 1982; Morrison et 
al., 1994). Targeting EBV by antiviral agents has been attempted also for prophylaxis of 
PTLD. However, the latent EBV infected cells which carries EBV genome and express a 
limited number of viral proteins are not eliminated by the use of antiviral agents. 
A potential approach for reducing the high risk of PTLD in EBV seronegative paediatric 
patients is to expose them to the EBV virus prior to transplantation to induce seroconversion 
and a vaccine using a viral membrane protein from EBV, gp350 (Gusy et al., 1995). 
10.4 Cytokine based therapy 
Agents that alter the cytokine environment of the tumour to favour remission, notably 
interferon-α and anti-IL-6 have been tried as adjuvant along with reduction of 
immunosuppression, but at present there is insufficient evidence to recommend their 
routine use. Interferon-α enhances T-lymphocyte cytotoxicity and has been used as an 
adjunct to chemotherapy to treat B cell malignancies in non-transplanted patients and in the 
maintenance of remission in such patients. Caution is needed when using interferon-α 
because of its toxicity and because it may initiate acute rejection by promoting CD8 T cell 
activity. 
IL-6 may play a role in the development of PTLD by promoting the growth of EBV-infected 
B cells and increasing tumour development in EBV-immortalised cells. Serum levels of IL-6 
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are raised in the majority of patients with PTLD. Anti-IL-6 mAb has been used in a phase 1–
2 multi-centre clinical trial (Hadda et al., 2000). 
10.5 Rapamycine 
Rapamycine is increasingly used as an immunosuppressive agent for solid organ 
transplantation. In addition to its immunosuppressive effects, it also displays anti-
angiogenic and anti-tumour properties, and this make it a potentially attractive agent for 
patients in remission from PTLD, particularly those who develop chronic allograft rejection 
as a consequence of a reduction of immunosuppression. Rapamycin inhibits the growth of 
EBV-transformed B lymphocyte lines in-vitro by arresting the cell cycle in the G1 phase 
(Vaysberg et al., 2007). There are as yet no prospective studies addressing the use of 
rapamycin in the treatment or prevention of PTLD. 
10.6 Adoptive T cell therapy 
Adoptive T cell therapy using EBV-specific cytotoxic T lymphocytes (CTL) lines has 
generated considerable interest as a treatment for PTLD. Adoptive immunotherapy was 
initially advocated in allogenic bone marrow transplantation to control PTLD that was 
donor cell in origin. Donor CTL would restore immune surveillance against EBV driven 
proliferation and control PTLD. A potential risk was graft versus host disease due to the 
donor cell infusion: this risk could be reduced by selecting donor EBV-specific T cell ex vivo 
prior to infusion. This approach has been used with success as prophylaxis and treatment of 
PTLD after stem cell transplantation using CTL lines derived from the donor and specific for 
EBV gene products even if it is limited by the time required to generate the CTLs (weeks to 
months) and the expense for dedicated facilities. 
After solid organ transplantation, PTLD is usually of recipient origin and recipient derived 
CTLs are required for effective killing of EBV infected B cells. It is possible to generate 
autologous EBV-specific CTLs from recipients who were EBV seropositive prior to 
transplantation. However, this approach is not applicable when PTLD arises in recipients 
who were EBV seronegative prior to transplantation.  
10.7 Chemotherapy 
Conventional cytotoxic chemotherapy which has been shown to be curative for many 
lymphomas in non-PTLD setting, has been viewed as a treatment of last resort due to very 
high morbidity and mortality rates. Chemotherapy is commonly used in the treatment of 
PTLD when reduction in immunosuppression fails to control the disease. 
Various multi-drug regimens such as CHOP or CHOP like (cyclophosphamide, 
doxorubicin, vincristine and prednisone) have been used in PTLD patients  (Wasson et al., 
2006; Elstrom et al., 2006; Trappa et al., 2007; Taylor et al., 2006; Fohrer et al., 2006; Baudi et 
al., 2007; Patel et al., 2007; Aversa et al., 2008) (table 4). 
In spite of the high RR up to 70%, the associated toxicity is significant and includes 
treatment-related deaths in about 25% of patients. The high mortality of the standard 
chemotherapy regimens in the PTLD population might occur because of various factors 
including baseline pharmacologic immunosuppression, graft dysfunction, and colonization 
with resistant or hospital acquired infectious organisms. 
Sepsis and other complication of chemotherapy have been the major problem in some 
centres, while others have found refractory disease to be common. Because this high 
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toxicity, several studies are in progress to investigate the use of other agents, such as anti-B 
cell mAb, in combination with lower dose and therefore less toxic chemotherapy regimes. 
 
 
Number of 
patients who 
received 
chemotherapy 
Chemotherapy response 
Therapy-
associated 
mortality 
 
Wasson 
et al, 
2006  
9 kidney 
transplant 
retrospective 
4 CHOP +/- R  
1 Ganciclovir  
2 Decreased 
immunosuppression  
1 Decreased 
immunosuppression + 
Rituximab  
1 Other chemotherapy  
n.a. None 
Trappe 
et al, 
2009  
 
58 kidney 
transplant 
prospective 
18 Rituximab 
40 CHOP +/- R 
40 CR 7 sepsis 
Fohrer et 
al, 2006  
17 kidney or 
kidney/pancreas 
transplant 
 prospective 
17  ACVBP 
 
13 CR + 
PR 
1 Infections 
Buadi et 
al, 2006  
14 kidney or 
kidney/pancreas 
transplant 
retrospective 
3 ProMACE CytaBOM  
1 CHOP-R  
1 BMT   
1 Rituximab 
6 Surgery  
2 Decreased 
immunosuppression  
8 CR  
1 PR 
2 SD 
3 NE 
 
 
Aversa 
et al, 
2008  
8 prospective 
7 VACOP-B  
1 STANFORD V  
7 CR  
1 PR  
2 TRM due to 
interstitial 
pneumonia 
CR: complete remission; PR: partial remission DFS : disease free survival; OS : overall survival; CHOP-R  
cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab; PMitCEBO: prednisone, 
mitoxantrone, cyclophosphamide, etoposide, bleomycin, vincristine; ACVBP: doxorubicin, 
cyclophosphamide, vindesine, bleomycin, prednisone; ProMACE CytaBOM:  cyclophosphamide, 
doxorubicin, etoposide, prednisone, bleomycin, vincristine, cytarabine, methotrexate, leucovorin; 
ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine; BMT: etoposide and cyclophosphamide 
followed by high dose melphalan and  autologous stem cell transplantation; VACOP-B: etoposide, 
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